Exelixis/EXEL

$21.74

-1%
-
1D1W1MYTD1YMAX

About Exelixis

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Ticker

EXEL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Morrissey

Employees

1,310

Headquarters

Alameda, United States

Exelixis Metrics

BasicAdvanced
$6.53B
Market cap
33.27
P/E ratio
$0.65
EPS
0.53
Beta
-
Dividend rate

What the Analysts think about Exelixis

Analyst Ratings

Majority rating from 20 analysts.
Buy

Price Targets

Average projection from 19 analysts.
23% upside
High $32.00
Low $18.00
$21.74
Current price
$26.74
Average price target

Exelixis Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
17.82% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$479.6M
1.63%
Net income
$85.5M
8,450%
Profit margin
17.82%
8,385.71%

Exelixis Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 27.08%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.12
$0.25
-
$0.27
-
Expected
$0.15
$0.16
$0.10
$0.21
$0.23
Surprise
-19%
56.25%
-
27.08%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Exelixis stock

Buy or sell Exelixis stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing